Confronto
Melanotan II vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
121062-08-6
396091-73-9
Peso molecolare
1024.18 g/mol
1047.21 g/mol
Emivita
1 h
nessun dato
Sequenza
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2nessun dato
Meccanismo d'azione
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
9
1
di cui sull'uomo
5
1
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
6
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Melanotan II and Pasireotid?
- Melanotan II is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Melanotan II or Pasireotid?
- The highest available evidence level is "Studio sull'uomo" for Melanotan II and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Melanotan II and Pasireotid in Germany and the United States?
- Germania: Melanotan II — Non approvato, Pasireotid — Su prescrizione. Stati Uniti: Melanotan II — Non approvato, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.